# Longevity & Cellular Health Research FAQ — Epitalon, MOTS-c, NAD+ — Supernova Peptides

> Frequently asked questions about Epitalon, MOTS-c, and NAD+ — three longevity and cellular health research agents — answered from peer-reviewed literature, with citations.

Direct, citation-grounded answers to the questions readers most often bring to these three longevity research agents.

## What is epitalon?

Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide — four amino acids in sequence Ala-Glu-Asp-Gly — derived from research on a bovine pineal gland extract called epithalamin. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology and is studied primarily as a *geroprotector*: a compound proposed to slow or modify cellular aging processes. Its two most-studied mechanisms are activating telomerase in somatic cells and stimulating pineal melatonin synthesis [1][4]. It is not an approved drug anywhere in the US, EU, or UK and is classified as a research chemical.

## What are the benefits of epitalon according to research?

The published research reports several findings, with important caveats about evidence strength. In human cell culture, Epitalon induced telomerase activity and extended telomere length in initially telomerase-negative cells [4], a result partially replicated in 2025 [2]. In mice, it extended maximum lifespan by 12.3% and inhibited leukemia 6-fold in a specific strain [6]. In rat pinealocyte culture, it raised melatonin levels [3]. An observational human cohort associated Epithalamin (the parent extract) with reduced mortality over 6-8 years [5]. None of this constitutes proven human anti-aging benefit: most data are preclinical, and human evidence is observational and not randomized [1][5].

## What is the recommended dosage of epitalon in research protocols?

This desk does not report human doses and cannot recommend any. Published animal studies used doses such as 1.0 µg/mouse subcutaneously in the SHR lifespan study [6] and 0.1–1 µg/mL in cell culture work [2]. No validated human pharmacokinetic study has been published — the peptide's half-life in humans is inferred from general short-peptide chemistry, not measured. Without human PK data, any circulating dose figure is extrapolation, not evidence. Dosing information in community forums is not grounded in controlled clinical research.

## How often should epitalon be cycled, once or twice a year?

There is no published clinical trial evidence establishing any cycling protocol for Epitalon in humans. The question reflects community practice, not a researched recommendation. The observational human cohort that reported mortality associations administered Epithalamin annually for six years [5], but that was the parent extract, not synthetic Epitalon, and the study design does not establish that any specific interval is optimal or safe. This desk does not give dosing or protocol advice.

## What does the MOTS-c peptide do?

MOTS-c is a mitochondria-encoded peptide that functions as a metabolic stress sensor. Its primary mechanism is inhibiting the folate cycle and de novo purine biosynthesis, which raises AICAR and activates AMPK — a master cellular energy sensor [10]. AMPK activation improves glucose uptake and insulin sensitivity in skeletal muscle and promotes antioxidant gene expression via NRF2. Under metabolic stress, MOTS-c also translocates to the cell nucleus and regulates gene expression directly [12]. A 2024 study identified casein kinase 2 (CK2) as a direct molecular binding target [8]. In aged mice, exogenous MOTS-c significantly improved physical performance [11].

## What are the negative side effects of MOTS-c?

No completed human intervention trials document MOTS-c adverse effects directly. The cautions come from the broader regulatory and research context: there are no validated human pharmacokinetics for MOTS-c; rodent doses (0.5-15 mg/kg/day) cannot be extrapolated to humans; and commercial research-chemical MOTS-c is not regulated for purity or sterility [10]. MOTS-c is treated as a prohibited substance in elite sport, so athletes face anti-doping sanctions for use. A natural variation in MOTS-c sequence (m.1382A>C mtDNA variant) is associated with elevated diabetes risk, which may suggest that the effects of this peptide are not uniformly positive across all genetic backgrounds.

## Is MOTS-c legal to buy?

MOTS-c is sold as a research chemical for laboratory use in most jurisdictions and is not scheduled as a controlled substance in the US or EU. That said, it is not approved for human use by the FDA or any major regulatory body, so its sale as a product for human consumption would violate regulatory requirements. In the context of competitive sport, MOTS-c is prohibited by anti-doping authorities including WADA under hormone and metabolic modulator categories — legal purchase for research does not imply permissibility in sport. Laws and regulations vary by jurisdiction; this desk does not give legal advice.

## How often do you inject MOTS-c?

This desk does not report human dosing or injection frequencies and cannot recommend any. Animal studies administering exogenous MOTS-c used daily or multiple-times-weekly regimens at doses like 0.5–15 mg/kg [11], but these were controlled experimental settings in mice — they are not human protocols. No human pharmacokinetic study has determined an appropriate dosing interval for MOTS-c in people. Community injection schedules circulating online are not grounded in human clinical research.

## What is NAD supplement used for?

NAD+ supplements — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are used to raise blood and tissue NAD+ levels, which decline with age [16]. The rationale is that restoring NAD+ may support the enzymes that depend on it — sirtuins (gene regulation, metabolic control), PARPs (DNA repair), and others — and thereby counter some aspects of metabolic aging. Human RCTs have shown that both NMN and NR reliably raise blood NAD+ [14][17]. Specific studied outcomes include improved muscle insulin sensitivity in prediabetic women [15] and improved walking distance in middle-aged adults [14]. Whether NAD+ supplementation extends lifespan or prevents age-related disease in humans has not been established [13].

## What is the downside of taking NAD+?

Several downsides are documented. Oral NAD+ itself is largely broken down before reaching the bloodstream intact — NMN and NR are considered the more rational oral forms because they are better absorbed [13]. Even with effective precursors, the 2025 *Nature Metabolism* review concludes human clinical evidence is still limited and tissue-specific NAD+ dynamics poorly characterized, so the premise that raising blood NAD+ reliably fixes age-related dysfunction is not yet proven [13]. IV-infused NAD+ can cause flushing, nausea, and chest discomfort if run too fast, and a compounded injectable preparation was recalled for endotoxin contamination. A theoretical concern exists that elevated NAD+ could support cancer cell metabolism. NMN's long-term supplement status is legally uncertain in the US.

## Is it safe to take NAD daily?

Published RCTs of oral NMN and NR suggest they are well tolerated with daily use in the study periods tested — up to 8-10 weeks at the doses studied [14][17]. The NR trial at doses up to 1000 mg/day for 8 weeks showed no significant adverse events, no LDL elevation, and no disruption of 1-carbon metabolism [17]. The NMN multicenter RCT found no safety issues at 300-900 mg/day for 60 days [14]. Long-term safety data beyond these trial periods, in older or medically complex populations, are not established. This desk summarizes the published evidence and does not make safety recommendations for any individual.

## Does NAD cause weight gain?

The published human trials do not document weight gain from NMN or NR supplementation. The 10-week NMN trial in prediabetic postmenopausal women found no change in body composition, including weight [15]. The multicenter NMN RCT did not report weight gain as an adverse finding [14]. The mechanistic biology actually points in the opposite direction: NAD+ supports sirtuin signaling and AMPK-related metabolic regulation that in animal models promote leanness and energy expenditure, not weight gain. There is no published clinical evidence that oral NAD+ precursors cause weight gain; this appears to be a concern not supported by the trial literature.

---

An independent literature desk mapping the published science on geroprotective compounds — citations in evidence, judgment reserved.